ABSTRACT Objective To clarify the relative contributions of amyloid and tau to synaptic dysfunction in Alzheimer's disease (AD). Methods We included 109 cognitively unimpaired and impaired individuals from the Geneva Memory Center with available CSF synaptic biomarkers (neurogranin, SNAP‐25, GAP‐43). Participants were...
Fausto Roveta, Augusto J. Mendes, V. Garibotto et al.· Annals of Clinical and Trans...· 0 citations
Findings support a 3-level interpretation of amyloid PET beyond binary classification and highlight the clinical relevance of the intermediate zone, which delineates biologically and clinically distinct stages along the amyloid continuum.
G. Mathoux, C. Boccalini, D. Peretti et al.· Journal of Nuclear Medicine· 0 citations
Ratios combining biomarkers of both amyloid and tau, such as Aβ42/pTau, consistently outperformed individual biomarkers in detecting amyloid and tau PET positivity and enhanced clinical utility by highlighting ambiguous cases requiring further assessment.
Sophie Mutel, F. Ribaldi, Augusto J. Mendes et al.· Alzheimer's Research & T...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.